Publications by authors named "Pengqiang Gao"
Article Synopsis
- Neoadjuvant chemoimmunotherapy (nCIT) shows better short-term outcomes than neoadjuvant chemotherapy (nCT) for patients with locally advanced esophageal squamous cell cancer (ESCC), particularly in terms of pathological responses and survival rates.
- A study analyzed 131 pairs of patients treated with nCIT or nCT, finding that nCIT led to higher rates of complete tumor response and improved surgical outcomes, including tumor down-staging and lymph node clearance.
- Although nCIT resulted in better disease-free survival (DFS) and overall survival (OS) at 3 years, further research is required to confirm long-term benefits.
Article Synopsis
- Neoadjuvant chemoimmunotherapy (NCIT) is being increasingly used as a treatment before surgery for esophageal squamous cell carcinoma (ESCC), but the patterns of lymph node metastasis after this therapy are not well understood.
- This study analyzed the cases of 257 patients who underwent NCIT and R0 resection and focused on the distribution and frequency of lymph node metastasis post-surgery.
- Results indicated that about 42.8% of patients had positive lymph nodes, with variability in metastasis patterns depending on the location of the thoracic tumor, providing insights that could guide future treatment strategies.
Chinese guidelines recommend POF (paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric cancer (AGC). Apatinib can augment the antitumor effect of paclitaxel, oxaliplatin, or fluorouracil in preclinical studies of AGC. A phase I clinical trial was conducted to evaluate the anticancer activity and maximum tolerated dose (MTD) of apatinib plus POF in treatment-naïve patients with AGC and to establish a recommended phase II dose.
View Article and Find Full Text PDFBackground: Choosing the appropriate treatment for elderly patients with esophageal cancer remains a contentious issue. While surgery is still a valid option, we aimed to identify predictors and outcomes in elderly esophagectomy patients with esophageal cancer.
Patients And Methods: We analyzed characteristics, surgical outcomes, survival rates, cause-specific mortality, and recurrence in 120 patients with stage I-IV esophageal cancer.
Article Synopsis
- The study investigates the combination of PD-1 inhibitors and varying intensities of neoadjuvant chemotherapy for patients with locally advanced esophageal squamous cell carcinoma (ESCC) before surgery.
- A total of 122 patients participated, receiving two or more cycles of the treatment, and results showed varying rates of pathological complete response (pCR) and major pathological response (MPR) based on chemotherapy dose intensity.
- The findings indicated a significant relationship between the intensity of chemotherapy and the likelihood of achieving MPR, with follow-up revealing a median survival of about 13.76 months post-surgery for those who survived.
Erratum: RPL35 promotes neuroblastoma progression via the enhanced aerobic glycolysis.
Am J Cancer Res
December 2022
[This corrects the article on p. 5701 in vol. 11, PMID: 34873488.
View Article and Find Full Text PDFLung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, and the leading cause of cancer-related deaths worldwide. G6PD has been reported to enhance the progression of various tumors by regulating the intracellular redox state and mediating nucleic acid synthesis. However, the biological role and molecular mechanism of G6PD in LUAD remain largely unknown.
View Article and Find Full Text PDFRPL35 promotes neuroblastoma progression via the enhanced aerobic glycolysis.
Am J Cancer Res
November 2021
Neuroblastoma (NB) is an rare type of tumor that almost affects children age 5 or younger due to its rapid proliferation ability. The overall survival rate of patients with advanced NB is not satisfactory. Ribosomal proteins (RPs) play a critical role in the development and progress of cancer.
View Article and Find Full Text PDFSafety of subxiphoid uniportal video-assisted thoracoscopic surgery for anterior mediastinal tumour in obese patients.
Wideochir Inne Tech Maloinwazyjne
June 2021
Introduction: Subxiphoid uniportal video-assisted thoracoscopic surgery (VATS) has been gradually applied for the treatment of anterior mediastinal tumour (AMT). However, whether obesity is a risk factor for subxiphoid uniportal VATS for AMT is still unknown.
Aim: To explore the safety and short-term outcome of subxiphoid uniportal VATS for AMT in obese patients.
Lung cancer is the leading cause of cancer-related mortality worldwide. Patients with locally advanced non-small cell lung cancer (NSCLC) have lower overall survival. Studies have shown that some patients with unresectable stage III NSCLC develop disease progression after initial chemoradiotherapy, and new treatment is needed to improve the prognosis of these patients.
View Article and Find Full Text PDF